Investing is a bit like an Ellery Queen mystery. If you can follow the clues you should find what you're seeking - upside.» Read More
NEW YORK, Oct 23- Aptalis Pharma Inc, a specialty drugmaker owned by private equity firm TPG Capital LP, has appointed underwriters for an initial public offering after efforts to sell the company failed, people familiar with the matter said on Wednesday.
*Sees 2013 revenue near midpoint of $19.5- $20.5 bln estimate. JERUSALEM, Oct 10- Teva Pharmaceutical Industries will cut about 5,000 jobs, 10 percent of its workforce, accelerating a cost-cutting plan as it prepares for lower-priced competition for its best-selling drug.
NEW YORK, Aug 30- A U.S. appeals court upheld the 2008 fraud conviction of money manager and arts patron Alberto Vilar, but ordered that he be resentenced, in a decision that may set back some government efforts to fight insider trading and other securities fraud.
*Akorn to pay $43.50/ Hi-Tech share. *Akorn sees annual savings of $15- $20 mln. Aug 27- Generic drugmaker Akorn Inc will buy rival Hi-Tech Pharmacal Co Inc for $640 million to expand its eye drug portfolio to oral liquids and ointments.
A new development suggests big companies may be getting fed up with Washington. Really fed up.
Sick of high U.S. corporate taxes? Here's how some companies are slashing their tax bill by 10%, 20%—or more.
Who’s best for the markets, Yellen or Summers? Wall Street debates while awaiting Obama’s pick for the next Fed chairman.
Cramer says a trio of recent deals demands attention.
Stocks kicked off the week on a weak note as investors hesitated to jump in ahead of the Federal Reserve meeting and a slew of key economic reports.
*Drug firm Perrigo to buy Elan; Publicis, Omnicom in merger. Shares of Southwestern Energy slid 3 percent to $38.14 and shares of Noble Energy fell 2.1 percent to $62.07 following as a decline in natural gas prices.
*Drug firm Perrigo to buy Elan; Publicis, Omnicom in merger. The energy sector led the day's losses, with the S&P energy index down 0.9 percent, while Caterpillar was up 0.9 percent at $82.82 and gave the Dow its biggest boost after announcing a $1 billion accelerated stock repurchase program.
*ECB and Bank of England meetings also awaited. NEW YORK, July 29- U.S. stocks slipped and the dollar came off a five-week low on Monday, a day ahead of the start of the Federal Reserve's two-day policy meeting, which is being keenly awaited for signs on when the U.S. central bank will begin to scroll back on its bond-buying program.
*Investors turn focus to data, signals from Fed on stimulus. *Drug firm Perrigo to buy Elan; Publicis, Omnicom in merger. NEW YORK, July 29- U.S. stocks fell on Monday as investor sentiment turned wary before a U.S.
*Drug firm Perrigo to buy Elan; Publicis, Omnicom in merger. NEW YORK, July 29- U.S. stocks dipped on Monday as a week packed with data and central bank meetings got under way, with the S&P 500 within a few points of its record close set a week ago. Federal Reserve, which will be combed for clues on when the Fed will begin to pare its $85 billion in monthly asset purchases.
This is a big week for macro news: a Federal Reserve meeting, an advance look at second-quarter U.S. growth, and July's nonfarm payroll report. But the bigger story may be the weakness of the U.S. dollar.
*Drug firm Perrigo to buy Elan; Publicis, Omnicom in merger. Pending-home sales data due at 10 a.m.. NEW YORK, July 29- U.S. stocks were set to slip at the open on Monday as a week packed with data and central bank meetings gets under way, with the S&P 500 just 0.2 percent below its record close set a week ago.
U.S. stock index futures ticked lower on Monday, ahead of the Federal Reserve meeting and another heavy week for second quarter earnings.
The Federal Reserve's taper talk may have rattled the financial markets but it has had one notable beneficiary: Mergers and acquisitions.
*Perrigo to buy Elan, Lord& Taylor's parent to acquire Saks. The European Central Bank and the Bank of England will also meet this week. On Monday, U.S. drugmaker Perrigo agreed to buy Elan for $8.6 billion.
*Elan surges after $8.6 bln takeover offer from Perrigo. Shares in Irish drugmaker Elan jumped 9 percent after U.S. peer Perrigo agreed to buy the firm for $8.6 billion, sparking a rally in pharma stocks, with Shire up 1.5 percent and Qiagen up 1 percent. France's Havas soared 6.3 percent and UK's WPP added 1.5 percent.